User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Search

Displaying 2 results.
    • Journal article
    A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2).
    Geven, Christopher Blet, Alice Kox, Matthijs Hartmann, Oliver Scigalla, Paul Zimmermann, Jens Marx, Gernot Laterre, Pierre-François[UCL] Mebazaa, Alexandre Pickkers, Peter (2019) BMJ open — Vol. 9, no.2, p. e024475 [1-11] (2019)
    • Journal article
    Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial.
    Laterre, Pierre-François[UCL] Pickkers, Peter Marx, Gernot Wittebole, Xavier[UCL] Meziani, Ferhat Dugernier, Thierry Huberlant, Vincent Schuerholz, Tobias François, Bruno Lascarrou, Jean-Baptiste Beishuizen, Albertus Oueslati, Haikel Contou, Damien Hoiting, Oscar Lacherade, Jean-Claude Chousterman, Benjamin Pottecher, Julien Bauer, Michael Godet, Thomas Karakas, Mahir Helms, Julie Bergmann, Andreas Zimmermann, Jens Richter, Kathleen Hartmann, Oliver Pars, Melanie Mebazaa, Alexandre AdrenOSS-2 study participants Castanares Zapatero, Diego[UCL] Collienne, Christine[UCL] Gérard, Ludovic[UCL] Hantson, Philippe[UCL] Montiel, Virginie[UCL] Berghe, Caroline[UCL] Dujardin, Marie-France[UCL] Gielens, Leslie[UCL] Renard, Suzanne[UCL] (2021) Intensive care medicine — Vol. 47, no.11, p. 1284-1294 (2021)